Table 3 Effect of any rhG-CSF use on metastasis following operation in NSCLC

 No rhG-CSF

61

16 (26.23%)

1

1

1

 rhG-CSF

246

119 (48.37%)

2.30 (1.36, 3.88)

< 0.01

2.41 (1.42, 4.11)

< 0.01

2.33 (1.31, 4.15)

< 0.01

 0

61

16 (26.23%)

1

1

1

 ≤ 500

96

49 (51.04%)

2.67 (1.52, 4.70)

< 0.01

2.86 (1.61, 5.08)

< 0.01

2.74 (1.50, 5.02)

< 0.01

 500–1000

85

38 (44.71%)

2.24 (1.25, 4.02)

< 0.01

2.32 (1.28, 4.18)

< 0.01

2.30 (1.20, 4.43)

0.01

 1000–1500

32

14 (43.75%)

1.63 (0.80, 3.35)

0.18

1.68 (0.81, 3.50)

0.16

1.48 (0.69, 3.18)

0.32

 > 1500

33

18 (54.55%)

2.29 (1.15, 4.57)

0.02

2.41 (1.20, 4.84)

0.01

2.16 (0.98, 4.47)

0.06

 p for trend

–

–

0.33

0.33

0.93

 0

67

19 (28.36%)

1

1

1

 < 15

71

34 (47.89%)

1.60 (0.91, 2.82)

0.10

1.65 (0.93, 2.92)

0.05

1.54 (0.82, 2.90)

0.18

 15–60

89

38 (42.70%)

1.76 (1.01, 3.06)

0.04

1.80 (1.03, 3.14)

0.04

1.50 (0.81, 2.81)

0.20

 60–200

38

20 (52.63%)

2.45 (1.30, 4.60)

< 0.01

2.73 (1.44, 5.18)

0.01

2.07 (1.04, 4.09)

0.04

 ≥ 200

42

24 (57.14%)

3.89 (2.12, 7.12)

< 0.01

3.80 (2.06, 7.01)

< 0.01

3.36 (1.77, 6.37)

< 0.001

 p for trend

< 0.001

< 0.001

< 0.001